RxDoctor Payments Data

Bernard Steyer, MD

Pulmonary Disease · Burlingame, CANPI 1699741454

Payments from drug & device makers

$2,480in general payments, 2019–2025

Across 103 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$901
  • Boehringer Ingelheim$266
  • Insmed, Inc.$195
  • AstraZeneca$154
  • Regeneron Healthcare Solutions, Inc.$105
  • Amgen$87
  • plus $772 from 24 others

What the payments were for

  • Food & beverage$2,474100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,480 in reported general payments places this provider in the 55th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$190,161
Medicare patients
489
Services billed
1,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter184$145,869
EliquisApixaban117$99,539
Breo ElliptaFluticasone/Vilanterol149$67,756
Dupixent PenDupilumab14$47,601
Spiriva RespimatTiotropium Bromide56$29,241
Arnuity ElliptaFluticasone Furoate82$20,194
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$19,732
XareltoRivaroxaban22$19,613
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$14,257
RybelsusSemaglutide15$14,246
Pirfenidone17$13,779
SymbicortBudesonide/Formoterol Fumarate37$12,574
Fluticasone-SalmeterolFluticasone Propion/Salmeterol57$7,913
Wellbutrin SrBupropion Hcl13$7,775
Wixela InhubFluticasone Propion/Salmeterol66$7,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta$901$253,952463 claims
PfizerEliquis$35$99,539117 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$266$48,97288 claims
AstraZenecaSymbicort, Pulmicort Flexhaler$154$18,06752 claims
MerckDulera$26$7,37215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →